Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (EMEA/V/MRL/003649/MODF/0004)
Guidance on the electronic submission of information on investigational medicinal products for human use in the Extended EudraVigilance medicinal product dictionary (XEVMPD)
Orphan designation: dibotatug Treatment of large granular lymphocytic leukaemia, 25/03/2026 Positive
Committee for Medicinal Products for Human Use (CHMP): 20-23 April 2026, European Medicines Agency, Amsterdam, the Netherlands, from 20 April 2026 to 23 April 2026
Annex to agenda of the CHMP meeting 20-23 April 2026
Agenda of the CHMP meeting 20-23 April 2026
Orphan designation: dusquetide Treatment of Behçet's Disease, 25/03/2026 Positive
Human medicines European public assessment report (EPAR): Roteas, edoxaban, Date of authorisation: 19/04/2017, Revision: 15, Status: Authorised
Human medicines European public assessment report (EPAR): Lixiana, edoxaban, Date of authorisation: 19/06/2015, Revision: 22, Status: Authorised
Human medicines European public assessment report (EPAR): Aclasta, zoledronic acid, Date of authorisation: 15/04/2005, Revision: 36, Status: Authorised